Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Prior treatment

• Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
• Receiving any investigational agent, that would be considered as a treatment for the primary neoplasm
• Received chemotherapy for lung cancer within 6 months of registration
• Previous chest radiotherapy that would overlap with the proton field

Other illness

• Distant metastases (M1 disease)
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, lupus, usual interstitial pneumonitis (UIP), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Active second malignancy
• History of myocardial infarction =\< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

Other

• Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:
  • Pregnant women
  • Nursing women
  • Men or women of childbearing potential who are unwilling to employ adequate contraception
• Weight loss of \> 10% in the past 3 months

• Age \>= 18 years
• Histological confirmation of non-small cell lung cancer
• Forced expiratory volume in 1 second (FEV1) \> 1.0 L
• Unresectable or medically inoperable stage 2-3 non-small cell lung cancer (based on computed tomography/positron emission tomography \[CT/PET\], magnetic resonance imaging \[MRI\] or CT of brain, and physical exam);
  • Eligible if recurrence after surgery and now has the equivalent stage 2-3 non-small cell lung cancer (NSCLC) OR had sub totally resected stage 2-3 NSCLC
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
• Negative pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only
• White blood cell (WBC) \>= 3.0 x 10\^9/L
• Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L
• Hemoglobin (Hgb) \>= 9 g/dl
• Platelets (plts) \> 100 x 10\^9/L
• Serum creatinine \< 1.5 x upper limits of normal (ULN)
• Serum bilirubin \< 1.5 x ULN
• Provide informed written consent
• Willing to return to enrolling institution for follow-up for a minimum of 1 year
• Ability to undergo potentially curative chemotherapy plus radiotherapy